In the current funding we found that although NK cells reconstitute in high numbers early after allogeneic transplant, they display diminished killer immunoglobulin receptors (KIR), they are hypo-responsive and poorly kill tumor targets. Using in vitro development models, we also found that the acquisifion of KIR and full effector function can be induced by IL-15. The overarching hypothesis of this Project is that NK cells eariy after hematopoetic transplantafion are uneducated and that NK cell education is developmentally regulated by IL-15, activafing receptors (2B4 Tim-3), and inhibitory receptor (KIR, NKG2A, LIR-1) ligation, all of which play a role in determining whether AML targets are killed. Promising results from Project 1 ofthe current funding show that allogeneic hematopoietic cell transplantafion with favorable KIR B haplotype donors (enhanced by a higher B content score and a Cen-B/B pattern) results in protecfion from AML relapse. In a second strategy (Project 3), a platform for NK cell adoptive transfer has been established. To improve on existing methods, the NCI has recently developed a cGMP process for production of rhlL-15 which will be made available to the Extramural community. SAI will test IL-15 as part of a novel strategy to expand adoptively transferred adult NK cells. A second course of IL-15 will be given on Day +42 to educate NK cells that reconstitute from CD34+ stem cells from the same donor. In SA2, we will invesfigate whether KIR immunogenetics determines NK cell function (the favorable Cen-B/B pattern found clinically) and whether IL-15 responsive KIR promoter elements control transcriptional regulation to form the KIR repertoire. SA3 will evaluate a novel activating receptor expressed on most NK cells, Tim-3, which is upregulated by IL-15. We hypothesize it plays a role in NK cell education.by upregulating the SAP adaptor (also IL-15 responsive) for 2B4. Tim-3 and 2B4 can directly recognize Galecfin-9 (Gal-9) and CD48 expressing AML targets or may indirectly receive activating signals from dendrific cells that express the same ligands. At complefion of these studies, we expect to change practice of NK cell adopfive transfer by use of IL-15 and to inform us about IL-15 mechanisms to induce NK cell education and recognifion of AML targets.
Patients with advanced AML often die of their disease. We hypothesize that optimally acfivated NK cells will provide effecfive therapy for these patients. Our studies propose a first in human testing of rhlL-15 to activate and expand NK cells in vivo. Our preliminary data supports a central role for IL-15 to educate NK cells by upregulating receptor expression and funcfion, which determine whether NK cells recognize AML targets.
|Williams, Robin L; Cooley, Sarah; Bachanova, Veronika et al. (2017) Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biol Blood Marrow Transplant :|
|Robinson, James; Guethlein, Lisbeth A; Cereb, Nezih et al. (2017) Distinguishing functional polymorphism from random variation in the sequences of >10,000 HLA-A, -B and -C alleles. PLoS Genet 13:e1006862|
|Schmohl, Jörg U; Felices, Martin; Oh, Felix et al. (2017) Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity. Cancer Res Treat 49:1140-1152|
|Cichocki, Frank; Valamehr, Bahram; Bjordahl, Ryan et al. (2017) GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity. Cancer Res 77:5664-5675|
|Davis, Zachary B; Vallera, Daniel A; Miller, Jeffrey S et al. (2017) Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Semin Immunol 31:64-75|
|Hoff, Gretchen A; Fischer, Johannes C; Hsu, Katharine et al. (2017) Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes. Biol Blood Marrow Transplant 23:153-160|
|Boyiadzis, Michael; Bishop, Michael R; Abonour, Rafat et al. (2016) The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer 4:90|
|Bachanova, Veronika; Weisdorf, Daniel J; Wang, Tao et al. (2016) Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation. Biol Blood Marrow Transplant 22:1602-1607|
|Weisdorf, Daniel (2016) The role of second transplants for leukemia. Best Pract Res Clin Haematol 29:359-364|
|He, F; Warlick, E; Miller, J S et al. (2016) Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD. Bone Marrow Transplant 51:1107-12|
Showing the most recent 10 out of 89 publications